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Abstract
Background: A recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi (rLdccys1) was previously
shown to induce protective immune responses against murine and canine visceral leishmaniasis. These findings encouraged
us to use rLdccys1 in the immunotherapy of naturally infected dogs from Teresina, Piauı´, a region of high incidence of
visceral leishmaniasis in Brazil.
Methodology/Principal Findings: Thirty naturally infected mongrel dogs displaying clinical signs of visceral leishmaniasis
were randomly divided in three groups: one group received three doses of rLdccys1 in combination with the adjuvant
Propionibacterium acnes at one month interval between each dose; a second group received three doses of P. acnes alone; a
third group received saline. The main findings were: 1) dogs that received rLdccys1 with P. acnes did not display increase of
the following clinical signs: weight loss, alopecia, onychogryphosis, cachexia, anorexia, apathy, skin lesions, hyperkeratosis,
ocular secretion, and enlarged lymph nodes; they also exhibited a significant reduction in the spleen parasite load in
comparison to the control dogs; 2) rLdccys1-treated dogs exhibited a significant delayed type cutaneous hypersensitivity
elicited by the recombinant antigen, as well as high IgG2 serum titers and low IgG1 serum titers; sera from rLdccys1-treated
dogs also contained high IFN-c and low IL-10 concentrations; 3) control dogs exhibited all of the clinical signs of visceral
leishmaniasis and had low serum IgG2 and IFN-c levels and high concentrations of IgG1 and IL-10; 4) all of the dogs treated
with rLdccys1 were alive 12 months after treatment, whereas dogs which received either saline or P. acnes alone died within
3 to 7 months.
Conclusions/Significance: These findings illustrate the potential use of rLdccys1 as an additional tool for the
immunotherapy of canine visceral leishmaniasis and support further studies designed to improve the efficacy of this
recombinant antigen for the treatment of this neglected disease.
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Introduction
Zoonotic visceral leishmaniasis (VL) is caused by Leishmania
(Leishmania) infantum chagasi in Mediterranean, Middle-East, Asian
countries, and Latin America and dogs are the main domestic
reservoirs of this zoonosis which has resulted in an annual in-
cidence of 40,100–75,000 new human cases [1,2]. A high human
VL incidence has been reported in Brazil mainly due to disease
urbanization as a consequence of human migration from rural
areas and ineffective vector and reservoir control [3–6]. Canine
VL control is based on either treatment or euthanasia of infected
animals. However, treatment of canine leishmaniasis with drugs
successfully used for human VL shows low efficacy and induces the
development of parasitic resistance to these drugs [7–10]. The
WHO thus strongly recommends that the same drugs should not
be used for treatment of dogs and humans in a same area [2]. On
the other hand, euthanasia of infected dogs is often unacceptable
for ethical and social reasons. Furthermore, the elimination of
infected dogs has shown controversial results in Brazil [11,12].
These issues led to the search of immunotherapy as a treatment
alternative for canine VL. The administration of L. (L.) infantum
chagasi extracts associated with the conventional chemotherapy of
naturally infected dogs resulted in a significant reduction in
infectivity [13]. Similar results were observed in dogs infected with
L. (L.) infantum chagasi that displayed a significant parasite burden
reduction after treatment with autoclaved L. (L.) major antigens
and heat killed Mycobacterium vaccae administered in conjunction
with Glucantime [14]. The healing efficacy of some vaccine
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candidates has also been tested. Treatment of infected dogs with
purified L. (L.) infantum chagasi LiF2 antigen in combination with
Glucantime led to the disappearance of clinical signs and a 100%
cure rate [15]. Dogs naturally infected with L. (L.) infantum chagasi
and treated with the recombinant vaccine Leish-110f formulated
with the adjuvant MPL-SE associated with Glucantime showed
clinical improvement, parasitological cure and increased survival
[16]. Recent data supported the effectiveness of this recombinant
vaccine for the treatment of mild cases of canine VL [17]. The
immunotherapeutic potential of the Leishmune vaccine alone or in
association with chemotherapy for canine VL treatment has also
been demonstrated [18–20].
A recombinant cysteine proteinase from L. (L.) infantum chagasi,
rLdccys1 was previously shown to be an useful immunological
marker for different VL stages in humans and dogs, and to offer an
appropriate diagnostic tool for human and canine VL [21–23].
Furthermore, immunization with either rLdccys1 or the gene
Ldccys1, which encodes the cysteine proteinase, induced significant
protection against L. (L.) infantum chagasi infection mediated by a
predominant Th1 response in a murine model of VL [24]. In that
study rLdccys1 was administered with P. acnes, a Gram-positive
bacillus, known to induce a prevalent Th1 immune response in
mice [25,26]. In earlier studies we used P. acnes as an adjuvant to
immunize BALB/c mice with native Ldccys1; this resulted in a
predominant Th1 response and a significant protection against
L. (L.) infantum chagasi challenge [27]. These results encouraged us
to evaluate the immunotherapeutic potential of rLdccys1 plus P.
acnes for naturally infected dogs from Teresina, Piauı´, a state in
Brazil with a high incidence of VL [28].
Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the Brazilian National Council of Animal
Experimentation (http://www.cobea.org.br). The protocol was
approved by the Committee on the Ethics of Animal Experiments
of the Institutional Animal Care and Use Committee at the
Federal University of Sa˜o Paulo (Id # CEP 1540/11).
Animals
A total of thirty dogs of different breeds, ages and sex were
provided by the Zoonosis Control Center in Teresina, Piauı´, in
Brazil, a VL endemic area. The animals were kept in a thin-
screened kennel in the Faculdade NOVAFAPI within Teresina,
Piauı´ state and fed commercially balanced animal food (Cherokee,
PRT, Brazil). Drinking water was provided ad libitum. Diagnostic
procedures were performed in the Department of Parasitology and
Microbiology at the Federal University of Piauı´. All dogs had been
pre-treated with anti-tick, anti-scabies and anti-helminthic drugs
and had been vaccinated against Parvovirus, Adenovirus type II,
Distemper, rabies (Defensor, Pfizer, EUA), Parainfluenza and
Corona viruses and Leptospirosis (Vanguard Plus, Pfizer, EUA).
Animals diagnosed with distemper, ehrlichiosis, and babesiosis
were excluded from the study. Animals with severe renal failure
(creatinine and urea values higher than 2.0 mg/dl and 35 mg/dl,
respectively) and pancytopenia (total leucocyte number lower than
6,000 and number per mm3 of erythrocytes and platelets lower
than 5.56103 and 200, respectively) were not included in the
study. All animals selected for immunotreatment tested positive for
leishmaniasis in parasitological, serological and biochemical
assays, had typical clinical signs of visceral leishmaniasis and were
never treated for canine leishmaniasis. Diagnosis was grounded on
positive bone marrow aspirate cultures, and ELISA assays using
an L. (L.) chagasi amastigote extract and rLdccys1 as antigens.
Additional laboratory studies included: complete blood cell counts,
biochemical assays (creatinine, urea, alkaline phosphatase, aspar-
tate aminotransferase, alanine aminotransferase, albumin, total
protein, glucose, and direct and indirect bilirubin). Clinical
parameters evaluated were: alopecia, anorexia, apathy, cachexia,
hyperkeratosis, size of lymph nodes, ocular secretion, onycho-
gryphosis, skin lesions and weight loss.
ELISA assays for dog screening
Microtiter plates (high binding, Costar, Corning Incorporated,
Corning, New York, USA) were coated with either 100 ng/well of
L. (L.) infantum chagasi lysates from amastigotes isolated from
spleens of L. (L.) infantum chagasi-infected hamsters as described
elsewhere [29] or with 200 ng/well of rLdccys1 in coating buffer
(0.05 M Na2CO3/NaHCO3, pH 9.6). The plates were incubated
overnight at 4uC and then blocked with 5% powdered skim milk in
PBS for 1 h. Canine sera were diluted 1:500, added to the plate
and incubated for 2 h at room temperature. After three washes
with 0.05% Tween 20 in PBS, peroxidase labeled antibodies
specific to canine IgG diluted 1:500 were added to the plate for
1 h at room temperature. The plates were then washed three times
with 0.05% Tween 20 in PBS, and the reaction developed with
0.5 mg/ml o-phenylenediamine in 0.05 M sodium citrate, pH 4.5,
containing 0.03% H2O2. The reaction was stopped by adding 4 N
H2SO4, and the absorbance was measured at 492 nm in a
Multiskan MS Plate Reader (Labsystems Oy, Helsinki, Finland).
The cut-off values were calculated by adding two S.D. values to
the mean absorbance of 20 dog normal sera.
Expression and purification of the recombinant cysteine
proteinase (rLdccys1)
The PCR product corresponding to the ORF of the Ldccys1
gene previously obtained [21] was subcloned into the Bam HI and
Eco RI restriction sites of the pHis-parallel 3 expression vector
in frame with an amino-terminal six histidine tag [30]. The
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zoonotic VL which has resulted in an annual incidence of
40,100–75,500 new human cases. Because canine VL
chemotherapy is limited by the low efficacy of drugs
currently used for human VL treatment, immunotherapy
may provide a viable alternative. We used a recombinant
cysteine proteinase from L. (L.) infantum chagasi, rLdccys1,
in combination with the adjuvant P. acnes for the
treatment of naturally infected mongrel dogs from
Teresina, Pauı´ a state in Brazil that has a high incidence
of VL. Dogs treated with rLdccys1 showed a significant
delayed type hypersensitivity reaction against the recom-
binant antigen and displayed high serum concentrations
of IgG2 and IFN-c and low concentrations of IgG1 and IL-
10. Immunotherapy with rLdccys1 resulted in no increase
of the clinical signs of canine VL and an extensive
reduction of spleen parasite load. Furthermore, all of the
dogs treated with rLdccys1 survived for at least 12 months
after treatment, whereas those that received either saline
or P. acnes alone died within 3 to 7 months. These findings
support the potential of rLdccys1 immunotherapy as an
additional option for the treatment of canine VL.
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recombinant plasmids were used to transform E. coli BL21 (DE3).
Protein expression was carried out by inoculating 500 ml of LB
medium containing 100 mg/ml ampicillin with a 25 ml overnight
bacterial culture. The suspension was kept in a rotatory shaker at
37uC until reaching log phase (Abs 600 nm = 0.6), and protein
expression was then induced with 0.2 mM IPTG for a further 3 h
at 37uC. After growth, the recombinant bacteria were pelleted at
4,0006 g for 10 min, and the recombinant antigen was then
purified from the insoluble inclusion bodies by affinity chroma-
tography using a Ni-NTA Superflow agarose matrix (QIAGEN),
according to Skeiky et al. [31]. Purified protein was analyzed by
SDS-PAGE and Western blotting using a previously described
monoclonal antibody directed against a cysteine proteinase of
30 kDa from L. (L.) amazonensis (MoAb 2E5D3) that cross reacts
with an antigen of 30 kDa from L. (L.) infantum chagasi amastigotes
[27,32].
Heat-killed Propionibacterium acnes suspension
P. acnes was obtained from Instituto Adolfo Lutz, Sa˜o Paulo,
S.P., Brazil and cultured as previously described [33]. Briefly, the
bacteria were grown in anaerobic medium (Hemobac, Probac,
Sa˜o Paulo, S.P., Brazil) for 3 days at 37uC and washed by
centrifugation. The resulting pellets were suspended in 0.9% saline
and subjected to continuous water vapor for 20 min at 120uC.
The protein concentration of the suspension was determined by
the Bradford method [34].
Dog treatment
The treatment protocol was performed with 30 mongrel dogs
selected by the parameters described in the ‘Animals’ section. All
selected dogs were positive for leishmaniasis in parasitological,
serological and biochemical assays and displayed clinical signs of
VL. After selection they were randomly divided into three groups
of 10 dogs each: one group received three subcutaneous doses of
500 mg rLdccys1 plus 500 mg P. acnes as an adjuvant on the back at
a one month interval; the second group received three doses of
P. acnes alone; and the third group received PBS. Half of the dogs
from each group were followed by monthly clinical examinations
until natural death, while the other half were euthanized three
months after the end of treatment.
Clinical evaluation
The development of the clinical signs of VL was described by a
score that quantifies the number of signs and discriminates mild
from severe signs. The scoring system for clinical signs was based
on the diameters of small (score = 1), and large lymph nodes
(score = 2). For mild and severe weight loss were given scores of 3
and 4, respectively. For alopecia, onychogryphosis, cachexia,
apathy, anorexia, hyperkeratosis, ocular secretion and skin lesions
were attributed a score of 3. The dogs were evaluated at time zero,
when they received the first dose, and monthly thereafter until two
months after the end of treatment (month 4). Clinical evaluation
was performed by a veterinarian which was blinded to the
treatment groups evaluated. Animals were looked for side effects of
the recombinant antigen such as local pain, local swelling, vomit
and diarrhoea. These signs were followed for 10 days after each
antigen injection.
Determination of parasite burden
Parasite burden was evaluated in the spleens of all dogs enrolled
in the study immediately after animal death using the limiting
dilution assay, as previously described [35], and parasite numbers
were determined from the highest dilution at which promastigotes
could be grown. Briefly, spleens were aseptically excised, weighed
and approximately 1–1.5 g of spleen tissue was collected from the
mid area and minced into small pieces with sterile scissors within a
sterile Petri dish. The tissue was homogenized in 1 ml of PBS and
further diluted in 199 medium (Gibco) containing 4.2 mM
NaHCO3, 40 mM HEPES, 1.0 mM adenine, 5 mg/ml hemin,
15% fetal bovine serum and 2% male human urine to obtain a
final concentration of 1 mg/ml. Serial dilutions ranging from 1 to
161026 were prepared in the same medium under sterile
conditions in 96 wells micro plates (Costar plates; Corning, Inc.,
Corning, NY). After incubation for 10 days at 26uC, plates were
examined using an optical microscope at 3-day intervals. The
reciprocal of the highest dilution that was promastigote positive
was considered to be the concentration of parasites in the spleen
tissue processed and the total parasite load was calculated by
multiplying this value by the total spleen weight.
Evaluation of immune responses
Delayed-type hypersensitivity assays (DTH) were performed by
intradermal injection of rLdccys1 (10 mg) into the inner surface of
the right thigh. As a negative control, each animal received an
injection of PBS into the inner surface of the left thigh. The
induration diameter was measured by use of a caliper after 24, 48
and 72 h, and each time the values of the saline control were
subtracted from the reaction due to the rLdccys1 antigen. Skin
reactions with diameter equal or larger than 5 mm were considered
positive. The DTH assays were carried out at time zero and one
month after animals received the third dose of rLdccys1.
Specific anti-rLdccys1 antibodies IgG, IgG1 and IgG2 isotypes
were evaluated by ELISA at time zero and one month after
administration of each dose of rLdccys1 in microtiter plates coated
with 200 ng/well of rLdccys1 according to the protocol described
in ‘‘ELISA assays for dog screening’’ section except that canine
sera were diluted 1:200. Peroxidase labeled antibodies specific to
canine IgG were diluted 1:500 and to IgG1 or IgG2 isotypes
(Bethyl Laboratories, Inc., Montgomery, TX, USA) were diluted
1:2000 and added to the plate for 1 h at room temperature. The
plates were then washed and the reaction developed as described
above.
Lymphokine concentrations were measured in dog sera at time
zero and one month after administration of each dose of rLdccys1
using a double-sandwich ELISA assay (Quantikine Canine IFNc
and IL-10) (R&D Systems). Microtiter plates (high-binding Costar
plates; Corning, Inc., Corning, NY) were coated overnight at 4uC
with specific mAb, which was directed to each lymphokine tested
and used at 100 ng/well. After washing with 0.05% Tween 20/
PBS (PBS/T) and blocking with PBS/T containing 5% skim milk
for 2 h at 37uC, 100 ml of dog sera diluted 1:2 were added to wells.
Standard curves were generated using recombinant canine IFNc
and IL-10. After incubation overnight at 37uC, plates were washed
with PBS/T, and a second antibody specific to each lymphokine
was added (biotinylated antibody diluted 1:250). After 60 min at
37uC, the plates were washed three times in 0.05% Tween 20 in
PBS, and the reaction was developed with 0.5 mg/ml of o-
phenylenediamine in 0.05 M sodium citrate, pH 4.5, containing
0.03% H2O2. The reaction was stopped by adding 4N H2SO4,
and the absorbance was measured at 492 nm in a Multiskan Plate
Reader (Labsystems Oy, Helsinki, Finland). Serum concentrations
higher than the minimal values obtained from the respective
standards were considered to be positive.
Statistical analysis
One-way ANOVA and Student’s t-test were used to determine
the significant differences between groups by use of GraphPad
Leishmania Cysteine Proteinase for Immunotherapy
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Prisma (version 5.0) and P values smaller than 0.05 (P,0.05) were
considered significant. The Pearson correlation coefficient was also
calculated by use of GraphPad Prisma (version 5.0).
Results
1) Reactivity of rLdccys1 in delayed–type hypersensitivity
(DTH) and humoral responses
Figure 1A shows that at time zero, selected dogs from each of
the groups exhibited low DTH values, whereas one month after
the end of treatment the DTH values were significantly higher in
dogs that received rLdccys1 compared to controls. The production
of total IgG at time zero and one month after administration of
each dose of rLdccys1 is shown in Figure 1B, while dosages of IgG1
and IgG2 are illustrated in Figure 1C. Starting from the first dose,
there was a significant increase of IgG production in the sera of dogs
treated with the recombinant antigen. Starting from the second dose,
there was also an increase of IgG production in sera from control
dogs, although this increase was lower than that observed in animals
treated with rLdccys1. The characterization of IgG subclasses
showed that there was a significant increase of IgG2 in animals
treated with rLdccys1, whereas IgG1 production was significantly
reduced after the second and third doses. In contrast, there was
constant production of IgG1 in controls during all treatment time
and a significant reduction of IgG2 starting from the first dose.
2) Determination of lymphokine production
IFN-c and IL-10 concentrations were measured by ELISA in
dog sera. Figure 2 shows that one month after the first dose there
was a low but significant IFN-c secretion in animals treated with
the recombinant antigen. Furthermore, an increased concentra-
tion of this lymphokine was observed after the second and third
doses of rLdccys1, while a low IL-10 concentration was detected in
these animals. In contrast, the control dogs exhibited a low IFN-c
concentration in all periods analyzed, as well as a significant IL-10
increase after they received the third dose of either P. acnes alone or
saline. These data indicate that the treatment with the recombi-
nant antigen led to the activation of Th1 responses.
3) Clinical evaluation
The evolution of clinical signs of VL is shown in Figure 3 and
Table S1. At time zero, animals from the three groups exhibited a
similar clinical score average (saline, 6.2; P. acnes, 4.9; rLdccys1
plus P. acnes, 6.3). Control animals exhibited a significant increase
of clinical signs that indicate disease progression two months after
the end of treatment. In contrast, there was no increase of clinical
signs in dogs treated with rLdccys1, indicating that they were able
to control the disease development. It is also important to
emphasize that clinical signs implicated in the severity of canine
VL, such as weight loss, cachexia and anorexia, were observed
only in control dogs (Table S1).
The safety of the recombinant antigen was also evaluated. The
number of dogs showing pain (25%) increased significantly from
the first to the third dose (P,0.001). The pain after each treatment
dose lasted for 48 h. Local swelling was the most common adverse
effect observed (67%) reaching an average diameter of 5 cm and
no significant differences among doses 1, 2 and 3 were noted.
Furthermore, in all dogs the local swelling reaction was transient
and decreased 24 h after each dose, disappearing five days after
injection. Dogs did not vomit or present diarrohea.
Figure 1. Delayed–type hypersensitivity and humoral responses induced by L. (L.) chagasi rLdccys1 in dogs treated with the
recombinant antigen compared with controls. (A) DTH evaluated at time zero and one month after the third dose of rLdccys1 (day 90) (n = 10
animals per group). P,0.001; (B and C) – Total IgG (B) and IgG1 and IgG2 (C) were evaluated by ELISA assay in the sera of treated dogs at time zero
and one month after each dose of rLdccys1. Plates were sensitized with 200 ng/well of rLdccys1 and the sera from all of the dogs (n = 10 animals per
group) were collected 30 days after each dose and diluted 1:200. *P,0.001; #P,0.05.
doi:10.1371/journal.pntd.0002729.g001
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The correlation between lymphokine production and clinical
score averages 30 days after the end of treatment with rLdccys1
is shown in Figure 4. The correlation between the production of
IFN-c and the clinical score averages is negative because there was
a significant increase of IFN-c followed by low clinical scores in
dogs treated with rLdccys1, whereas in the controls the low
secretion of IFN-c was correlated with an increase in clinical signs
(Figure 4A). In contrast, there is a direct correlation between IL-10
production and the clinical score average. A significant increase in
IL-10 and clinical score averages was observed in controls, while
there was a decrease in IL-10 secretion followed by low clinical
scores in dogs treated with rLdccys1 (Figure 4B).
4) Evaluation of the dog survival and parasite load
The survival of controls and dogs treated with rLdccys1 was
followed until the natural death of half of the L. (L.) chagasi-infected
animals. Most of the dogs that received saline died between 2.6
and 4.4 months after the end of treatment. Among these animals,
one was observed to have the lowest clinical score average and
survived until 6 months after treatment. Among the dogs treated
with P. acnes, three died between 2.8 and 5.3 months, while two of
them survived 6.6 and 6.7 months after treatment. In contrast,
dogs treated with rLdccys1 died after 12.3 to 14.2 months, with a
mean survival time two times higher than the controls (Figure 5A).
Figure 5B shows the parasite load evaluated by limiting dilution
analysis in dog spleens after death. Animals treated with rLdccys1
exhibited a seven-log reduction in parasite burden compared to
controls that received either saline or P. acnes alone.
The other half of the dogs that were euthanized three months
after the end of treatment showed a lower parasite burden
compared to animals followed until natural death. However, the
parasite burden reduction in rLdccys1-treated dogs was not
significantly different between euthanized and non-euthanized
animals (data not shown).
Discussion
The main problems that face the treatment of leishmaniasis are
toxicity, high cost and parasitic resistance to leishmanicidal drugs
currently available on the market. This scenario is even more
pronounced in the case of canine VL due to the low efficacy of the
drugs currently in use for treatment of infected dogs [36]. All of
these issues have pointed to the immunological stimulation as an
attractive option for the treatment of leishmaniasis [37]. With this
rationale, the potential of a recombinant cysteine proteinase of
Figure 3. Clinical evaluation. Outcome of clinical scores in controls and dogs treated with rLdccys1. Each point represents the average of clinical
scores from treated dogs that were evaluated on time zero until two months following the end of treatment (n = 10 animals per group). *P,0.001.
doi:10.1371/journal.pntd.0002729.g003
Figure 2. Levels of IFN-c (A) and IL-10 (B) in dog sera. (A) IFN-c was quantified at time zero and one month after each dose of rLdccys1. (B) IL-
10 was quantified at time zero and one month after the third dose of rLdccys1 (n = 10 animals per group) *P,0.001; #P,0.05.
doi:10.1371/journal.pntd.0002729.g002
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L. (L.) infantum chagasi, rLdccys1, for the treatment of canine VL
was investigated in this study. The usefulness of this recombinant
antigen was first demonstrated in screening naturally infected dogs
selected for this study. Similar values were observed when either
rLdccys1 or L. (L.) infantum chagasi extracts were used as antigens in
ELISA assays for evaluation of humoral responses (data not
shown). These findings corroborate previous results that demon-
strated the high sensitivity and specificity of rLdccys1 for the
diagnosis of canine and human VL [21,23]. In this study, a
significant increase of DTH responses was observed after
treatment with rLdccys1, supporting our previous results on the
use of rLccys1 to distinguish between asymptomatic and symp-
tomatic canine VL [23].
Data on antibody production showed an increase of total IgG in
all animal groups during the treatment; however this increase was
higher in the rLdccys-treated dogs. Furthermore, rLdccys1-treated
dogs had increased IgG2 production and decreased IgG1, while
control animals exhibited lower antibody levels with predomi-
nance of IgG1. Although the IgG1 and IgG2 subclasses have been
used as more reliable indicators of the CVL status than total IgG
[38], recently, the functional characterization of canine IgG
subclasses raised doubts about the correlation of IgG subclasses
with Th1 or Th2 responses [39]. However, our findings are
compatible with those that showed high levels of IgG1 anti-
Leishmania antibodies associated with the development of clinical
signs in L. (L.) infantum chagasi-infected dogs, while IgG2 antibodies
appear to be associated with asymptomatic infection [40]. Fur-
thermore, protective responses in dogs vaccinated with the re-
combinant A2 protein appear to be associated with increased
levels of total IgG and IgG2 but not with those of IgG1 anti-A2
antibodies [41]. Our data on DTH and humoral responses in
rLdccys1-treated dogs are also compatible with those reported in
dogs infected with L (L.) infantum chagasi subjected to immuno-
therapy with the Leishmune vaccine [18,20].
The treatment with rLdccys1 resulted in a significant increase of
IFN-c, reduction in IL-10, and significantly less progressive clinical
disease than control groups. In contrast, the control dogs pre-
sented the opposite profile of these lymphokines and a significant
Figure 4. Correlation between lymphokine production and the average of clinical scores in controls and treated dogs one month
after treatment with rLdccys1. Data are depicted in a bivariate correlation graph between individual clinical signs and levels of IFN-c (A) and IL-10
(B) in controls (PBS or P. acnes) and dogs treated with rLdccys1. P,0.001.
doi:10.1371/journal.pntd.0002729.g004
Figure 5. Survival (A) and parasite load (B) of controls and dogs treated with rLdccys1. The parasite load was evaluated by limiting
dilution analysis in the spleen of the dogs immediately after animal death. *P,0.05. Bars represent the standard error of the mean and horizontal
lines represent the average of parasite load. The standard deviations are 3.782e+017, 2.108e+017, and 2.256e+010, for PBS, P. acnes, and P. acnes +
rLdccys1 groups, respectively.
doi:10.1371/journal.pntd.0002729.g005
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increase of clinical signs until four months after treatment. Indeed,
a significant negative correlation was found between the number
of clinical signs and IFN-c production in dogs treated with
rLdccys1, whereas a positive correlation was observed between the
production of IL-10 and an increase of clinical signs in control
dogs. These results strengthen the implication of IFN-c and IL-10
in control and progression, respectively of canine VL. The
induction of Th1 cells producing IFN-c, IL-2 and TNF-a has
been associated with protection against canine VL [42,43]. The
activation of macrophages by IFN-c to kill intracellular amasti-
gotes via the L-arginine nitric oxide pathway is the main effector
mechanism involved in the protective immune responses of dogs
infected with L. (L.) chagasi infantum [44,45]. In contrast, IL-10 has
been correlated with disease progression and an increase in IL-10
levels; this was observed in the spleens of dogs naturally infected
with L. (L.) infantum chagasi [46]. IL-10 mRNA transcripts were
detected in Con A-stimulated PBMC derived from dogs with VL
clinical signs [43,47]. It is worth noting that among the rLdccys1-
treated dogs, the first animal that died exhibited a higher clinical
score mean at screening, as well as a lower level of serum IFN-c
one month after the end of treatment (data not shown). These
findings indicate that the effectiveness of the rLdccys1 treatment is
dependent on the disease progression at the time of inclusion in the
study. It is possible that sick animals with lower levels of IL-10
respond better to antigen stimulation. Similar results were
observed in dogs developing severe VL that did not respond to
Leish-111f vaccine treatment [17]. These considerations point to
the treatment of asymptomatic dogs with rLdccys1 and a potential
more pronounced Th1 response in these animals.
It is also important to emphasize the choice of the adjuvant used
in the present study. P. acnes treatment elicits a type-1 (Th1)
immune response involving IL-12 and IL-18 that induces IFN-c
release, enhancement of the IgG2a switch and Th2 expansion
inhibition [25,26]. Administration of killed P. acnes as an adjuvant
increased the resistance to infection by Trypanosoma cruzi [48]. In
leishmaniasis, the treatment with P. acnes led to the control of
L. (L.) major infection in BALB/c mice [49]. Murine vaccination
with the A2 antigen from L. (L.) donovani plus P. acnes resulted in a
mixed Th1 and Th2 response with a predominance of Th1
responses after the homologous challenge, as well as a significant
parasite burden decrease in immunized animals [50]. Our pre-
vious data on immunization of BALB/c mice with either the
native or recombinant Ldccys1 plus P. acnes followed by challenge
with L. (L.) infantum chagasi also showed a predominant Th1
response and a significant parasite burden decrease in immunized
animals [24,27]. Immunization of dogs with rLdccys1 plus P. acnes
also resulted in a significant protection against L. (L.) infantum
chagasi infection (unpublished data).
The participation of CD8+ lymphocytes in protective immune
responses triggered in dogs treated with rLdccys1 was not ad-
dressed in this study but cannot be overlooked. Analysis of the
predicted amino acid sequence of the L. (L.) infantum chagasi Ldccys1
gene cloned previously showed one potential MHC class I epitope
for CD8+ lymphocytes in addition to two MHC class II epitopes
[21]. The involvement of CD8+ lymphocytes in canine VL has
been demonstrated [51] and increased levels of these cells appear
to be the major phenotypic feature of asymptomatic disease [52].
Enhanced expression of CD8+ lymphocytes was also observed in
L. (L.) infantum chagasi-infected dogs after treatment with the
Leishmune vaccine and resulted in a significant reduction of VL
clinical signs and parasite burden levels [18,20].
Immunotherapy with rLdccys1 increased the survival time of
L. (L.) infantum chagasi-infected dogs. Comparable results were
reported following the use of Glucantime and the recombinant
Leish-110f vaccine for treatment of dogs naturally infected with
L. (L.) infantum chagasi [16]. Contrary to our findings, animals
subjected to that immunotherapeutic protocol had a reduced
number of deaths. Nevertheless, treated animals were followed
until 180 days after treatment, while in our study animals were
monitored until their natural death, and all of the rLdccys1-treated
dogs were alive up until one year after treatment. Use of the Leish-
110f vaccine in infected dogs treated for longer period of time also
resulted in lower death rates compared to our results [17]. Again,
this study was different from our treatment protocol because the
authors emphasized the advantage of a weekly vaccine schedule
over antigen administration with 3 or 4 weeks intervals [17].
Higher survival rates were also observed in dogs treated with the
Leishmune vaccine [18–20]. It is important to highlight that the
differences among previous studies on immunochemotherapy and
the present study, including treatment schedules, adjuvant, geo-
graphical factors, and disease status of the dogs, hinder the
comparison with our data. It is still important to mention that only
symptomatic dogs with a high parasite burden were selected for
our study and presumably treatment with rLdccys1 of animals
with lower parasite burden may lead to improved results.
Despite the high parasitism levels found within the infected dogs
enrolled in the present study, there was a significant lesser parasite
burden in dogs treated with rLdccys1 compared to controls.
Nevertheless, dog cure and a pronounced decrease of vector
infectivity are desirable goals in regions of high VL endemicity. In
this context, we believe that the use of booster doses of rLdccys1
associated to allopurinol, the drug recommended by WHO to treat
CVL [2], are promising to improve the effectiveness of treating
CVL with this recombinant antigen.
In conclusion, our findings showed the potential of rLdccys1 as
an additional tool for immunotherapy of canine VL and support
further studies to evaluate its healing efficacy with a larger number
of dogs, as well as in different regions of VL incidence.
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